cp wire

CP Wire Articles

Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Eli Lilly (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer'... read more

Tue, 06/12/18 - 09:02 am
FIRALIS has developed BIOPRED panel to better target inflammatory autoimmune diseases
Key points of the Biopred panel: 
  • Without extraction - no biases associated to extractions steps
  • More than 2100 mRNA target... read more
Mon, 06/11/18 - 10:12 am
Bacteriophages Used Successfully to Treat GI Distress

Results from a new clinical study have confirmed the safety and tolerability of using bacteria-specific viruses known as bacteriophages to eliminate disease-causing bacteria in the gut. The new... read more

Mon, 06/11/18 - 10:02 am
Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens
  •  Company just announced 24% cut in workforce
  • First patient is being treated for non-small cell lung cancer
  • ADXS-NEO generates T cell responses against neoantigen peptides... read more
Mon, 06/11/18 - 09:33 am
Allergan's Migraine Prevention Drug Meets Primary Endpoints in Ph Iib/III Study



  • Atogepant met primary endpoint for all doses and dose regimens
  • Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over... read more
Mon, 06/11/18 - 09:07 am

Pages